Markets:

Overview

News

Currencies

International

Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

131.02 -0.04 (-0.03%)

Streaming Delayed Price Updated: 10:38 AM EDT, May 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗

May 10, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

Via The Motley Fool

Traders are paying attention to the gapping stocks in Monday's session. ↗

May 04, 2026

Via Chartmill

Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib ↗

March 25, 2026

Via Chartmill

Topics Earnings

Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In ↗

December 02, 2025

Via The Motley Fool

Discover the top movers in Monday's pre-market session. ↗

May 04, 2026

Via Chartmill

Why Celcuity Stock Popped on Monday ↗

April 27, 2026

An analyst initiated coverage of the biotech.

Via The Motley Fool

Why Celcuity Stock Popped Today ↗

March 26, 2026

The cancer-focused biotech published its final set of figures for 2025.

Via The Motley Fool

The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026

March 24, 2026

As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗

March 20, 2026

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Via The Motley Fool

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing ↗

March 10, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Closes Position in GEO Stock, Sells $17.6 Million Worth of Shares, According to Recent SEC Filing ↗

March 10, 2026

This corrections firm delivers facility management and reentry services to government clients in the U.S., Australia, and South Africa.

Via The Motley Fool

Topics Immigration Regulatory Compliance

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rotation of 2026: Why Small-Cap 'Underdogs' are Finally Outpacing the Tech Titans

March 04, 2026

The first quarter of 2026 has ushered in a dramatic reversal of the decade-long market hierarchy. After years of trailing in the shadow of mega-cap technology giants, small-cap stocks—the perennial...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Apis Capital Expands Garrett Motion Stake as Hybrid Demand Extends the Combustion Cycle ↗

February 26, 2026

Apis Capital Advisors increased its stake in Garrett Motion, a key supplier of turbocharging systems used in combustion and hybrid vehicles. With global auto production still dominated by hybrid and...

Via The Motley Fool

Topics Economy Emissions Regulatory Compliance

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump ↗

February 06, 2026

Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

3 Stocks You’ll Wish You Bought Before 2026 ↗

December 03, 2025

Via MarketBeat

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗

November 28, 2025

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗

November 27, 2025

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Via The Motley Fool

Topics Regulatory Compliance

GEO Shares Down 44% as Fund Sells $9 Million in Stock Amid ICE Allegations and Softer Outlook ↗

November 27, 2025

GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings guidance—here’s what investors need to know.

Via The Motley Fool

Topics Immigration Regulatory Compliance

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.